Results 131 to 140 of about 16,132,005 (307)
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski +10 more
wiley +1 more source
e-Learning to create a community of learning and practice for supply chain management in healthcare
The article advances and describes a new way to strengthen the capacity of health workers in the domain of supply chain management of medicines. Although the focus on SCM in health is relatively recent, a well-functioning supply chain system embedded ...
Griet Samyn, Manusika Rai, Carole Piriou
doaj
Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola +11 more
wiley +1 more source
Lecanemab (Leqembi©, Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer’s disease (AD) in several countries, including the US and Japan.
Alessandro Martorana +3 more
doaj +1 more source
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
BackgroundThis study aimed to investigate the association between continuous polypharmacy and hospitalization, emergency department (ED) visits, and death.MethodsThis retrospective study utilized 6,443,896 patients aged between 65 and 84 years of ...
Jungmi Chae +3 more
doaj +1 more source
Development and utilization of the Medicines Use Review patient satisfaction questionnaire
Ali Hindi,1 Caroline Parkhurst,1,2 Yasamin Rashidi,1 Shun Yan Ho,1 Nilesh Patel,1 Parastou Donyai11Department of Pharmacy, University of Reading, Berkshire, UK; 2Professional Services Department, Day Lewis Pharmacy Group, Croydon, London, UK Abstract ...
Parkhurst C +5 more
core
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur +11 more
wiley +1 more source
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi +11 more
wiley +1 more source

